11:58 AM
 | 
Feb 16, 2018
 |  BC Week In Review  |  Clinical News  |  Regulatory

EC approves Celltrion's Herceptin biosimilar

Celltrion Inc. (KOSDAQ:068270) said the European Commission approved Herzuma, a biosimilar of cancer drug Herceptin trastuzumab from Roche (SIX:ROG; OTCQX:RHHBY) and its Genentech Inc. unit. The...

Read the full 108 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >